Advertisement

Klinische Aspekte der Immunsuppression

  • Rudolf Peter Wüthrich
Chapter

Zusammenfassung

Kortikosteroide, zytotoxische Medikamente (Azathioprin und Cyclophosphamid) und Ciclosporin bilden die Grundlage der immunsuppressiven Therapie nach Nierentransplantation. Diese Pharmaka können in verschiedenen Kombinationen oder im Falle von Ciclosporin als Monotherapie angewendet werden. Verschiedene Protokolle und deren Erfolgsrate sind in zahlreichen klinischen Studien beschrieben worden. Die Tripeltherapie mit Prednison, Azathioprin und Ciclosporin hat sich in vielen Zentren als bewährte Behandlungsform durchgesetzt. Dies erlaubt, die Dosis der einzelnen Medikamente niedrig zu halten und gleichzeitig doch eine ausgezeichnete immunsuppressive Wirkung zu erzielen. Im folgenden sollen die klinisch relevanten Immunsuppressiva beschrieben und ihre Anwendung besprochen werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bennett WM, Barry JM (1979) Failure of dexamethasone to provide adequate chronic immunosuppression for renal transplantation. Transplantation 27: 218PubMedCrossRefGoogle Scholar
  2. 2.
    Byyny RL (1976) Withdrawal from glucocorticoid therapy. N Engl J Med 295: 30PubMedCrossRefGoogle Scholar
  3. 3.
    Canafax DM, Mann HJ, Sutherland DER, Simmons RL, Najarían JS (1983) The use of a cosyntropin stimulation test to predict adrenal suppression in renal transplant patients being withdrawn from prednisone. Transplantation 36: 143PubMedCrossRefGoogle Scholar
  4. 4.
    Chan L, French EM, Beare, Oliver DO, Morris PJ (1980) Prospective trial of high-dose versus low-dose prednisolone in renal transplant patients. Transplant Proc 12: 323PubMedGoogle Scholar
  5. 5.
    D’Apice AJF, Becker GJ, Kincaid-Smith P, Mathew TH, Ng J, Hardie IR, Petrie JJB, Rigby RJ, Dawborn J, Heale WF, Miach PJ (1984) A prospective randomized trial of low-dose versus high-dose steroids in cadaveric renal transplantation. Transplantation 37: 373PubMedCrossRefGoogle Scholar
  6. 6.
    De Vecchi A, Cantaluppi A, Montagnino G, Maestri O, Ponticelli C (1980) Long-term comparison between single-morning daily and alternate-day steroid treatment in cadaver kidney recipients. Transplant Proc 12: 327PubMedGoogle Scholar
  7. 7.
    Dumler F, Levin NW, Szego G, Vulpetti AT, Preuss LE (1982) Long-term alternate day steroid therapy in renal transplantation. A controlled study. Transplantation 34: 78Google Scholar
  8. 8.
    Dupont E, Wybran J, Toussaint C (1984) Glucocorticosteroids and organ transplantation. Transplantation 37: 331PubMedCrossRefGoogle Scholar
  9. 9.
    Frey BM, Frey FJ (1984) Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 14: 1PubMedCrossRefGoogle Scholar
  10. 10.
    Gambertoglio JG, Amend WJC, Benet LZ (1980) Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm 8: 1PubMedCrossRefGoogle Scholar
  11. 11.
    Gambertoglio JG, Frey FJ, Holford NHG, Birnbaum JL, Stanik-Lizak P, Vincenti F, Feduska NJ, Salvatierra O, Amend WJC (1982) Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int 21: 621PubMedCrossRefGoogle Scholar
  12. 12.
    Gambertoglio JG, Holford NHG, Kapusnik JE, Nishikawa R, Saltiel M, Stanik-Lizak P, Birnbaum JL, Hau T, Amend WJC (1984) Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int 25: 119PubMedCrossRefGoogle Scholar
  13. 13.
    Gambertoglio JG, Holford NHG, Stanik-Lizak P, Birnbaum JL, Salvatierra O, Amend WJC (1984) The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients. Am J Kidney Dis 3: 425PubMedGoogle Scholar
  14. 14.
    Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O, Amend WJC (1980) Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. J Clin Endocrinol Metab 51: 561PubMedCrossRefGoogle Scholar
  15. 15.
    Glass NR, Miller DT, Sollinger HW, Beizer FO (1983) A comparative study of steroids and heterologous antiserum in the treatment of renal allograft rejection. Transplant Proc 15: 617Google Scholar
  16. 16.
    Gore SM, Oldham JA (1986) Randomized trials of high-versus-low dose steroids in renal transplantation. Does the evidence favor a consensus? Transplantation 41: 319PubMedCrossRefGoogle Scholar
  17. 17.
    Haynes RC, Murad F (1985) Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of adrenocortical steroid biosynthesis. In: Gilman AG, Goodman CS, Rail TW, Murad F (eds) The pharmacological basis of therapeutics, chap 63. Macmillan, New York, pp 1459 - 1489Google Scholar
  18. 18.
    Häyry P, Ahonen J, Kock B, Eklund B, Kauste A, Koskimies S, von Willebrand E (1984) Glucocorticoids in renal transplantation: Impact of high-versus-low dose postoperative methylprednisolone administration on graft survival and on the frequency and type of complications. Scand J Immunol 19: 211Google Scholar
  19. 19.
    Häyry P, von Willebrand E, Ahonen J, Eklund B (1982) Glucocorticoids in renal transplantation: Impact of high-versus-low dose postoperative methylprednisolone administration on the first episode(s) of rejection. Scand J Immunol 16: 39Google Scholar
  20. 19a.
    Hricic DE, Almawi WY, Strom TB (1994) Trends in the use of glucocorticoids in renal transplantation. Transplantation 57: 979Google Scholar
  21. 20.
    Kawai S, Ichikawa Y, Homma M (1985) Differences in metabolic properties among Cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab 60: 848PubMedCrossRefGoogle Scholar
  22. 21.
    McGeown MG, Douglas JF, Brown WA, Donaldson RA, Kennedy JA, Loughridge WG, Metha S, Nelson SD, Doherty CC, Johnstone R, Todd G, Hill CM (1980) Advantages of low dose steroid from the day after renal transplantation. Transplantation 29: 287PubMedCrossRefGoogle Scholar
  23. 22.
    McGeown MG, Kennedy JA, Loughridge WGG, Douglas J, Alexander JA, Clarke SD, McEvoy L, Hewitt JC, Nelson SD (1977) One hundred kidney transplants in the Belfast City Hospital. Lancet 2: 648PubMedCrossRefGoogle Scholar
  24. 23.
    Melby JC (1977) Clinical pharmacology of systemic corticosteroids. Annu Rev Pharmacol Toxicol 17: 511PubMedCrossRefGoogle Scholar
  25. 24.
    Morris PJ, French ME, Chan L, Ting A (1982) Low dose oral prednisolone in renal transplantation. Lancet 1: 525PubMedCrossRefGoogle Scholar
  26. 25.
    Nelson AM, Conn DL (1980) Glucocorticoids in rheumatic disease. Mayo Clin Proc 55: 758PubMedGoogle Scholar
  27. 26.
    Papadakis J, Brown CB, Cameron JS, Adu D, Bewick M, Donaghey R, Ogg CS, Rudge C, Williams DG, Taube D (1983) High-versus-low dose corticosteroids in recipients of cadaveric kidneys: prospective controlled trial. Br Med J 286: 1097CrossRefGoogle Scholar
  28. 27.
    Park GD, Bartucci M, Smith MC (1984) High-versus-low dose methylprednisolone for acute rejection episodes in renal transplantation. Nephron 36: 80PubMedCrossRefGoogle Scholar
  29. 28.
    Pickup ME (1979) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 4: 111PubMedCrossRefGoogle Scholar
  30. 29.
    Ponticelli C, De Vecchi AF, Tarantino A, Rivolta E, Egidi FM, Berardinelli L, Vegeto A (1983) A search for optimizing corticosteroid administration to renal transplant patients. Kidney Int 23 (suppl. 14):S–85Google Scholar
  31. 30.
    Salaman JR (1983) Steroids and modern immunosuppression. Br Med J 286: 1373CrossRefGoogle Scholar
  32. 31.
    Salaman JR, Griffin PJA, Price K (1983) High or low dose steroids for immunosuppression. Transplant Proc 15: 1086Google Scholar
  33. 32.
    Sells RA, Brookes L, Basu P, Whitemore D (1978) Methylprednisolone blood levels in cadaveric renal allograft recipients. Transplant Proc 10: 651PubMedGoogle Scholar
  34. 33.
    Sherlock JE, Letteri JM (1977) Effect of hemodialysis on methylprednisolone plasma levels. Nephron 18: 208PubMedCrossRefGoogle Scholar
  35. 34.
    Silberman H (1981) Dosage of corticosteroids in renal allograft rejection. Am J Surg 142: 413PubMedCrossRefGoogle Scholar
  36. 35.
    Steinman TI, Zimmerman CE, Monaco AP, Brown RS, Yager HM, Clive DM, Ransil BJ (1981) Steroids can be stopped in kidney transplant recipients. Transplant Proc 13: 323PubMedGoogle Scholar
  37. 36.
    Stewart PM, Corrie J, Seckl JR, Edwards CRW, Padfield PL (1988) A rational approach for assessing the hypothalamopituitary-adrenal axis. Lancet 1: 1208PubMedCrossRefGoogle Scholar
  38. 37.
    Ubhi CS, Woodhouse L, Giles GR (1990) Interaction of intravenous methylprednisolone with orla cyclosporin. Nephrol Dial Transplant 5: 376PubMedGoogle Scholar
  39. 38.
    Wassner S J, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Fine RN (1977) Allograft survival in patients receiving anticonvulsant medications. Clin Nephrol 8: 293PubMedGoogle Scholar
  40. 1.
    Bach JF, Dardenne M (1971) The metabolism of azathioprine in renal failure. Transplantation 12: 253PubMedCrossRefGoogle Scholar
  41. 2.
    Bedrossian CWM, Sussman J, Conklin RH, Kahan B (1984) Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol 82: 148PubMedGoogle Scholar
  42. 3.
    Campos H, Kreis HA, Rioux P, Crosnier J (1984) Azathioprine withdrawal in renal transplant recipients. Transplantation 38: 29PubMedCrossRefGoogle Scholar
  43. 4.
    Chan GLC, Canafax DM, Johnson CA (1987) The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 7: 165PubMedGoogle Scholar
  44. 5.
    Dandavino R, Trunet P, Descamps B, Kreis H (1978) Prolonged withdrawal of azathioprine in kidney transplantation. Transplant Proc 10: 655PubMedGoogle Scholar
  45. 6.
    D’Apice AJF, Becker GJ, Kincaid-Smith P, Mathew TH, Ng J, Hardie IR, Petrie JJB, Rigby RJ, Dawborn J, Heale WF, Miach PJ (1984) A prospective randomized trial of low-dose versus high-dose steroids in cadaveric renal transplantation. Transplantation 37: 373PubMedCrossRefGoogle Scholar
  46. 7.
    DeClerck Y A, Ettenger RB, Ortega JA, Pennisi AJ (1980) Macrocytosis and pure RBC anemia caused by azathioprine. Am J Dis Child 134: 377Google Scholar
  47. 8.
    Dretchen KL, Morgenroth VH, Standaert FG, Walts LF (1976) Azathioprine: effects on neuromuscular transmission. Anesthesiology 45: 604PubMedCrossRefGoogle Scholar
  48. 9.
    Fisher KA, Mahajan SK, Hill JL, Stuart FP, Katz AI (1976) Prediction of azathioprine intolerance in transplant patients. Lancet 1: 828PubMedCrossRefGoogle Scholar
  49. 10.
    Haesslein HC, Pierce JC, Lee HM, Hume DM (1972) Leukopenia and azathioprine management in renal homotransplantation. Surgery 71: 598PubMedGoogle Scholar
  50. 11.
    Hogge DE, Wilson DR, Shumak KH, Cattran DC (1982) Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient. Can Med Assoc J 126: 512PubMedGoogle Scholar
  51. 12.
    Huskisson EC (1984) Azathioprine. Clin Rheum Dis 10: 325Google Scholar
  52. 13.
    Iwasaki Y, Ozaki A, Fukao K, Iwasaki H, Rapaport FT (1982) Withdrawal of immunosuppressive drugs after renal transplantation - a world survey. Transplant Proc 14: 225Google Scholar
  53. 14.
    Klippel JH, Decker JL (1974) Relative macrocytosis in cyclophosphamide and azathioprine therapy. JAMA 229: 180PubMedCrossRefGoogle Scholar
  54. 15.
    Liano F, Moreno A, Matesanz R, Teruel JL, Redondo C, Garcia- Martin F, Orte L, Ortuno J (1989) Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause? Nephron 51: 509PubMedCrossRefGoogle Scholar
  55. 16.
    Loertscher R, Brunner FP, Harder F, Thiel G (1983) Withdrawal of azathioprine in renal transplant patients with chronic active hepatitis: Is it wise or not. Nephron 33: 150Google Scholar
  56. 17.
    Mallory A, Kern F (1980) Drug-induced pancreatitis: a critical review. Gastroenterology 78: 813PubMedGoogle Scholar
  57. 18.
    McGrath BP, Ibels LS, Raik E, Hargrave M, Mahony JF, Stewart JH (1975) Erythroid toxicity of azathioprine. Q J Med 44: 57PubMedGoogle Scholar
  58. 19.
    Millard PR, Herbertson BM, Evans DB, Calne RY (1973) Azathioprine hepatotoxicity in renal transplantation. Transplantation 16: 527CrossRefGoogle Scholar
  59. 20.
    Nicholls AJ, Davidson RJL (1979) Development of macrocytosis during azathioprine therapy after renal transplantation. Transplantation 27: 220PubMedCrossRefGoogle Scholar
  60. 21.
    Old CW, Flannery EP, Grogan TM, Stone WH, San Antonio RP (1978) Azathioprine-induced pure red blood cell aplasia. JAMA 240: 552PubMedCrossRefGoogle Scholar
  61. 22.
    Paloyan D, Levin B, Simonowitz D (1977) Azathioprine-associated acute pancreatitis. Dig Dis 22: 839CrossRefGoogle Scholar
  62. 23.
    Pollak R, Nishikawa RA, Mozes MF, Jonasson O (1980) Azathioprine-induced leukopenia - clinical significance in renal transplantation. J Surg Res 29: 258PubMedCrossRefGoogle Scholar
  63. 24.
    Ramalho HJ, Terra EG, Cartapatti E, Barberato JB, Alves VAF, Gayotto LCC, Abbud-Filho M (1989) Hepatotoxicity of azathioprine in renal transplant recipients. Transplant Proc 21: 1716PubMedGoogle Scholar
  64. 25.
    Read AE, Wiesner RH, LaBreque DR, Tifft JG, Mullen KD, Sheer RL, Petrelli M, Ricanati ES, McCullough AJ (1986) Hepatic venoocclusive disease associated with renal transplantation and azathioprine therapy. Ann Int Med 104: 651PubMedGoogle Scholar
  65. 26.
    Saway PA, Heck LW, Bonner JR, Kirklin JK (1988) Azathioprine hypersensitivity: case report and review of the literature. Am J Med 84: 960PubMedCrossRefGoogle Scholar
  66. 27.
    Schusziarra V, Ziekursch V, Schlamp R, Siemensen HC (1976) Pharmacokinetics of azathioprine under hemodialysis. Int J Clin Pharmacol 14: 298Google Scholar
  67. 28.
    Singh G, Fries JF, Spitz P, Williams CA (1989) Toxic effects of azathioprine in rheumatoid arthritis. Arthritis Rheum 32: 837PubMedCrossRefGoogle Scholar
  68. 29.
    Sparberg M, Simon N, del Greco F (1969) Intrahepatic cholestasis due to azathioprine. Gastroenterology 57: 439PubMedGoogle Scholar
  69. 30.
    Spiers ASD, Mibashan RS (1974) Increased warfarin requirement during mercaptopurine therapy: a new drug interaction. Lancet 2: 221PubMedCrossRefGoogle Scholar
  70. 1.
    DeFronzo RA, Braine H, Colvin OM (1973) Water intoxication in man after cyclophosphamide therapy. Ann Int Med 78: 861Google Scholar
  71. 2.
    Finn GP, Sidau B, Shaw IC (1986) Protecting the bladder from cyclophosphamide with mesna. N Engl J Med 314: 61PubMedGoogle Scholar
  72. 3.
    Gershwin ME, Goetzl EJ, Steinberg AD (1974) Cyclophosphamide: Use in practice. Ann Int Med 80: 531Google Scholar
  73. 4.
    Pedersen-Bjergaard J, Ersbell J, Hansen VL, Sorensen BL, Christoffersen K, Hou-Jensen K, Nissen NI, Knudsen JB, Hansen MM (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-hodgkin’s lymphoma: N Engl J Med 318: 1028PubMedGoogle Scholar
  74. 5.
    Starzl TE, Groth CG, Putnam CW, Corman J, Halgrimson CG, Penn I, Husberg B, Gustafsson A, Cascardo S, Geis P, Iwatsuki S (1973) Cyclophosphamide for clinical renal and hepatic transplantation. Transplant Proc 5: 511PubMedGoogle Scholar
  75. 6.
    Starzl TE, Putnam CW, Halgrimson CG, Schroter GT, Martineau G, Launois B, Corman JL, Penn I, Booth AS, Grooth CG, Porter KA (1971) Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet 133: 981PubMedGoogle Scholar
  76. 7.
    Yadav RVS, Induhara R, Kumar P, Chugh KS, Gupta KL (1988) Cyclophosphamide in renal transplantation. Transplantation 45: 421PubMedCrossRefGoogle Scholar

Allgemeine Literatur

  1. 1.
    Borel JF, Feurer C, Gubler HU, Stähelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB (1984) Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Int Med 101: 667Google Scholar
  3. 3.
    Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725CrossRefGoogle Scholar
  4. 4.
    Kahan BD, Flechner SM, Lorber MI, Jensen C, Golden D, Van Buren CT (1986) Complications of cyclosporine therapy. World J Surg 10: 348PubMedCrossRefGoogle Scholar
  5. 5.
    Nelson PW (1984) Cyclosporine. Surg Gynecol Obstet 159: 297Google Scholar
  6. 6.
    Stähelin H (1986) Cyclosporin: Historical background. Prog Allergy 38: 19PubMedGoogle Scholar
  7. 7.
    Van Buren CT (1986) Cyclosporine: Progress, problems, and perspectives. Surg Clin North Am 66: 435PubMedGoogle Scholar
  8. 8.
    White DJG, Calne RY (1982) The use of cyclosporin A. Immunosuppression in organ grafting. Immunol Rev 65: 115Google Scholar

Pharmakokinetik

  1. 9.
    Albrechtsen D, Berg KJ, Rugstad HE, Sodal G, Fiatmark A (1986) Blood and plasma cyclosporine levels in renal transplantation. Transplant Proc 18: 44Google Scholar
  2. 10.
    Hammond PG, Forland SC, Al-Bander H, Cutler RE (1990) Drugs and the kidney. In: Gonick HC (ed) Current nephrology, vol 13, chap 8. Year Book Medical Publishers, Chicago, pp 263 - 311Google Scholar
  3. 11.
    Kahan BD, Grevel J (1988) Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46: 631PubMedCrossRefGoogle Scholar
  4. 12.
    Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15: 446Google Scholar
  5. 13.
    Kahan BD, Wideman CA, Reid M, Gibbons S, Jarowenko M, Flechner S, Van Buren CT (1984) The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc 16: 1195PubMedGoogle Scholar
  6. 14.
    Lindholm A, Hendricsson S (1989) Simultaneous monitoring of cyclosporine in blood and plasma with four analytical methods: A clinical evaluation. Transplant Proc 21: 1472Google Scholar
  7. 15.
    Ptachcinski RJ, Venkataramanan R, Burckart GJ (1986) Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11: 107PubMedCrossRefGoogle Scholar

Medikamenteninteraktionen

  1. 16.
    Baciewicz AM, Baciewicz FA (1989) Cyclosporine pharmacokinetic drug interactions. Am J Surg 157: 264PubMedCrossRefGoogle Scholar
  2. 17.
    Butler RT, Kalkwarf KL, Kaidahl WB (1987) Drug-induced gingival hyperplasia: phenytoin, cyclosporine, and nifedipine. J Am Dental Assoc 114: 56Google Scholar
  3. 18.
    Hourmant M, Le Bigot JF, Vernillet L, Sagniez G, Remi JP, Soulillou JP (1985) Coadministration of erythromycin results in an increase of blood cyclosporine to toxic levels. Transplant Proc 17: 2723Google Scholar
  4. 19.
    Lake KD (1988) Cyclosporine drug interactions: a review. Cardiac Surgery: State of the Art Reviews 2 (4): 617Google Scholar
  5. 19a.
    Patton PR, Brunson ME, Pfaff WW, Howard RJ, Peterson JC, Ramos EL, Karlix JL (1994) A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 57: 889Google Scholar
  6. 20.
    Uhbi CS, Woodhouse L, Giles GR (1990) Interaction of intravenous methylprednisolone with oral cyclosporin. Nephrol Dial Transplant 5: 376Google Scholar
  7. 21.
    Wadhwa NK, Schroeder TJ, Pesce AJ, Myre SA, Clardy CW, First MR (1987) Cyclosporine drug interactions: a review. Ther Drug Monit 9 (4): 399PubMedCrossRefGoogle Scholar

Klinische Anwendung

  1. 22.
    Calne RY (1987) Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet 2: 506PubMedCrossRefGoogle Scholar
  2. 23.
    Canadian Multicentre Transplant Study Group (1986) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 314: 1219CrossRefGoogle Scholar
  3. 23a.
    Helderman JH, Van Buren DH, Amend WJC, Pirsch JD (1994) Chronic immunosuppression of the renal transplant patient. J Am Soc Nephrol 4 (Suppl 1): S2PubMedGoogle Scholar
  4. 23b.
    Hricic DE, Kupin WL, First MR (1994) Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 4 (Suppl 1): S10Google Scholar
  5. 24.
    Johnson RWG, for the European Multicentre Trial Group (1986) Cyclosporine in cadaveric renal transplantation: three-year follow-up of a European Multicentre Trial. Transplant Proc 18: 1229Google Scholar
  6. 25.
    Jones RM, Murie JA, Allen RD, Ting A, Morris PJ (1988) Triple therapy in cadaver renal transplantation. Br J Surg 75: 4PubMedCrossRefGoogle Scholar
  7. 26.
    Kropp KA, Wolfe C, Jhunjhunwala JS, Selman SH (1989) Cyclosporine versus azathioprine: a review of 200 consecutive cadaver renal transplant recipients. J Urol 142: 28PubMedGoogle Scholar
  8. 27.
    Lewis RM, Janney RP, Golden DL, Kerr NB, Van Buren CT, Kerman RH, Kahan BD (1989) Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy - five year follow-up. Transplantation 47: 266PubMedCrossRefGoogle Scholar
  9. 28.
    Merion RM, White DJG, Thiru S, Evans DB, Calne RY (1984) Cyclosporine: five years’ experience in cadaveric renal transplantation. N Engl J Med 310: 148PubMedCrossRefGoogle Scholar
  10. 28a.
    Mueller EA, Kovarik JM, Van Bree JB, Lison AE, Kutz K (1994) Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 57: 1178PubMedCrossRefGoogle Scholar
  11. 29.
    Zehnder C, Beveridge T, Nüesch E, Abisch A, Thiel G (1988) Cyclosporine A capsules: bioavailability and clinical acceptance study in renal transplant patients. Transplant Proc 20 (Suppl 2): 641PubMedGoogle Scholar

Nebenwirkungen

  1. 30.
    Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Grotto AM, Young JB (1989) Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262: 53PubMedCrossRefGoogle Scholar
  2. 31.
    Bantle JP, Nath KA, Sutherland DER, Najarian JS, Ferris TF (1985) Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Int Med 145: 505CrossRefGoogle Scholar
  3. 32.
    Coffman TM, Carr DR, Yarger WE, Klotman PE (1987) Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 43: 282PubMedCrossRefGoogle Scholar
  4. 33.
    Curtis JJ (1990) Cyclosporine-induced hypertension. In: Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology, diagnosis, and management, chap 113. Raven Press, New York, pp 1829 - 1835Google Scholar
  5. 34.
    Keown PA, Stiller CR (1987) Cyclosporine: a double-edged sword. Hosp Pract (May 15 issue): 207Google Scholar
  6. 35.
    Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH (1989) Cyclosporine-induced hyperuricemia and gout. N Engl J Med 321: 287PubMedCrossRefGoogle Scholar
  7. 36.
    Mihatsch MJ, Thiel G, Ryffel B (1988) Cyclosporine nephrotoxicity. Adv Nephrol 17: 303Google Scholar
  8. 37.
    Myers BD et al. (1988) The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33: 590PubMedCrossRefGoogle Scholar
  9. 38.
    Myers BD, Ross J, Newton L, Luetscher J, Perlroth M (1984) Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699PubMedCrossRefGoogle Scholar
  10. 39.
    Taube DH, Williams DG, Hartley B, Rudge CJ, Neild GH, Cameron JS, Ogg CS, Welsh KI (1985) Differentiation between allograft rejection and cyclosporine nephrotoxicity in renal transplant recipients. Lancet 2: 171PubMedCrossRefGoogle Scholar
  11. 40.
    Scherrer U et al. (1990) Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 323: 693PubMedCrossRefGoogle Scholar
  12. 41.
    Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD (1985) De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 98: 54PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Rudolf Peter Wüthrich
    • 1
  1. 1.Departement für innere Medizin Abt. für NephrologieUniversitätsspital ZürichZürichSwitzerland

Personalised recommendations